Were Eric Dube’s Travere Therapeutics (TVTX) share sales pre-planned?

Yes. The filing states the sales were made under a written trading plan adopted June 16, 2025 that meets Rule 10b5-1(c) requirements. Such plans pre-schedule trades, reducing the significance of timing decisions by the executive.

Travere (NASDAQ: TVTX) CEO nets 64,000 PSUs, sells shares under plan

Filing Impact

(Very High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Travere Therapeutics, Inc. director and CEO Eric M. Dube reported a PSU vesting and related share sales. On April 13, 2026, he acquired 64,000 shares of common stock at no cost through vested performance restricted stock units, triggered by FDA approval of FILSPARI (sparsentan) in FSGS.

On April 15, 2026, he sold 56,815 shares at a weighted average price of $41.01, 7,165 shares at a weighted average price of $41.75, and 20 shares at $42.66, all in open-market transactions under a Rule 10b5-1 trading plan that also covered tax obligations from the PSU vesting. Following these transactions, he directly holds 432,886 shares of Travere common stock, the same level as before the grant and sales.

Insights

CEO’s Form 4 shows PSU vesting with offsetting, pre-planned sales.

Eric M. Dube received 64,000 shares via performance restricted stock units after FDA approval of FILSPARI in FSGS, then sold an equal 64,000 shares in three open-market blocks at prices around $41–$43. The filing shows these were routine compensation-related events.

The sales were executed under a written Rule 10b5-1(c) plan adopted on June 16, 2025 and include shares sold to cover tax obligations from the PSU vesting. After the grant and sales, Dube’s direct holdings remain 432,886 shares, indicating no net change in his equity stake from these transactions alone.

Insider Trade Summary 10b5-1

Net Seller: 64,000 shares ($2,629,975)

Net Sell 4 txns

Insider Dube Eric M

Role CHIEF EXECUTIVE OFFICER

Sold 64,000 shs ($2.63M)

Type	Security	Shares	Price	Value
Sale	Common Stock	56,815	$41.01	$2.33M
Sale	Common Stock	7,165	$41.75	$299K
Sale	Common Stock	20	$42.66	$853.20
Grant/Award	Common Stock	64,000	$0.00	--

Holdings After Transaction: Common Stock — 440,071 shares (Direct)

Footnotes (1)

On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units. The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Key Figures

PSU shares vested: 64,000 shares Shares sold at $41.01: 56,815 shares at $41.01 Shares sold at $41.75: 7,165 shares at $41.75 +5 more

8 metrics

PSU shares vested 64,000 shares Performance restricted stock units vested on April 13, 2026

Shares sold at $41.01 56,815 shares at $41.01 Open-market sale on April 15, 2026; weighted average price

Shares sold at $41.75 7,165 shares at $41.75 Open-market sale on April 15, 2026; weighted average price

Shares sold at $42.66 20 shares at $42.66 Open-market sale on April 15, 2026

Total shares sold 64,000 shares Aggregate of three open-market sale transactions on April 15, 2026

Holdings after transactions 432,886 shares Direct common stock ownership following grant and sales

PSU grant date January 31, 2025 Date PSUs were originally granted to CEO

10b5-1 plan adoption date June 16, 2025 Date written trading plan for sales was adopted

Key Terms

performance restricted stock units (PSUs), Rule 10b5-1(c), weighted average sale price, U.S. Food and Drug Administration (FDA), +2 more

6 terms

performance restricted stock units (PSUs) financial

"the reporting person was granted performance restricted stock units (PSUs) which PSUs vested"

Rule 10b5-1(c) regulatory

"written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c)"

Rule 10b5-1(c) is an SEC guideline that lets company insiders set up a written, pre-planned schedule to buy or sell their company stock when they are not in possession of material, nonpublic information. For investors, it matters because such plans can reduce the appearance of insider trading by separating decisions from inside knowledge—like putting your trades on autopilot—while also requiring scrutiny since pre-planned trades can still affect market confidence and share value.

weighted average sale price financial

"The weighted average sale price for the transaction reported was $41.01"

U.S. Food and Drug Administration (FDA) regulatory

"upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval"

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

FILSPARI (sparsentan) medical

"FDA had granted approval of FILSPARI (sparsentan) in FSGS"

FSGS medical

"approval of FILSPARI (sparsentan) in FSGS"

Focal segmental glomerulosclerosis (FSGS) is a kidney disease in which small sections of the organ’s filtering units become scarred, lowering their ability to remove waste and manage fluids. Investors care because drug candidates, diagnostics, or clinical trial results addressing FSGS can meaningfully affect a biotech or pharmaceutical company’s revenue prospects and regulatory outlook—like fixing a specific engine fault that can restore performance and change a vehicle’s value.

Form 4 Insider Transactions: What Each Field Means →

04/15/2026 - 09:48 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dube Eric M

(Last)

(First)

(Middle)

C/O TRAVERE THERAPEUTICS, INC.

3611 VALLEY CENTRE DR., SUITE 300

(Street)

SAN DIEGO

CALIFORNIA

92130

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Travere Therapeutics, Inc. [ TVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CHIEF EXECUTIVE OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/13/2026		A⁽¹⁾		64,000	A	$0	496,886	D
Common Stock	04/15/2026		S⁽²⁾		56,815	D	$41.01⁽³⁾	440,071	D
Common Stock	04/15/2026		S⁽²⁾		7,165	D	$41.75⁽⁴⁾	432,906	D
Common Stock	04/15/2026		S⁽²⁾		20	D	$42.66	432,886	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On January 31, 2025, the reporting person was granted performance restricted stock units (PSUs) which PSUs vested on April 13, 2026 upon the Issuer's confirmation that the U.S. Food and Drug Administration (FDA) had granted approval of FILSPARI (sparsentan) in FSGS.

2. This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of performance restricted stock units.

3. The weighted average sale price for the transaction reported was $41.01, and the range of prices were between $40.51 and $41.51. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. The weighted average sale price for the transaction reported was $41.75, and the range of prices were between $41.52 and $42.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Elizabeth E. Reed, Attorney-in-Fact	04/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Travere Therapeutics (TVTX) CEO Eric Dube acquire in this Form 4?

Eric Dube acquired 64,000 shares of Travere common stock at no cost through vested performance restricted stock units. These PSUs vested when the FDA approved FILSPARI (sparsentan) in FSGS, converting into actual shares of stock for the CEO.

How many Travere Therapeutics (TVTX) shares did the CEO sell and at what prices?

Eric Dube sold a total of 64,000 Travere common shares in three trades: 56,815 shares at a weighted average of $41.01, 7,165 shares at $41.75, and 20 shares at $42.66. All transactions were open-market sales of common stock.

Why did the Travere Therapeutics (TVTX) CEO sell shares after PSU vesting?

The filing explains that the sales include shares sold to cover tax obligations arising from the vesting of performance restricted stock units. This is a common practice, where part of an equity award is sold to pay income and payroll taxes due.

How many Travere Therapeutics (TVTX) shares does the CEO own after these transactions?

After the PSU grant and subsequent sales, Eric Dube directly owns 432,886 shares of Travere common stock. This holding level is unchanged compared with before the 64,000-share PSU vesting and the corresponding 64,000 shares sold in the market.

What FDA milestone triggered the Travere Therapeutics (TVTX) PSU vesting?

The performance restricted stock units vested when the FDA approved FILSPARI (sparsentan) for FSGS. Upon the issuer’s confirmation of this approval, the PSUs granted January 31, 2025 converted into 64,000 shares of common stock for Eric Dube.